Track market-moving stories before they get noisy

Key Takeaways Insulet launched Omnipod 5 and Omnipod Discover in Spain, expanding its global footprint.Spain is the 20th Omnipod 5 country and 26th Omnipod market for the company.Omnipod 5 is approved in Spain for type 1 diabetes patients aged two years and older. Insulet Corporation (PODD - Free Report) has commercially launched its Omnipod 5 Automated Insulin Delivery (AID) system and the Omnipod Discover data management platform in Spain, further expanding its international footprint. Spain becomes the 20th country where Omnipod 5 is available and the 26th market where the company sells its Omnipod products, marking another step in Insulet’s ongoing global expansion strategy.

From an investor’s perspective, the launch reinforces Insulet’s commitment to broadening the reach of its flagship automated insulin delivery platform across international markets. Spain’s sizable population of people living with diabetes presents a meaningful long-term growth opportunity, while the addition of the Omnipod Discover platform enhances the company’s digital care ecosystem and strengthens its value proposition for patients and healthcare providers. The continued rollout of Omnipod 5 is expected to support international revenue growth and deepen Insulet’s competitive position in the global diabetes technology market.

Likely Trend of PODD Stock Following the NewsShares of PODD have traded flat since the announcement on July 6. In the year-to-date period, shares of the company have lost 43.2% compared with the industry’s 20.8% decline. The S&P 500 increased 10.4% in the same time frame.

The Spain launch is expected to strengthen Insulet’s long-term growth trajectory by expanding the addressable market for its Omnipod 5 platform and reinforcing its leadership in the global insulin delivery market. As reimbursement coverage broadens across Spain’s autonomous regions, the company stands to benefit from a growing base of recurring, high-margin Pod sales.

Moreover, the introduction of the Omnipod Discover platform enhances Insulet’s connected diabetes care ecosystem, improving patient engagement and supporting stronger relationships with healthcare providers. Continued international expansion of its automated insulin delivery platform is likely to drive sustained revenue growth, increase market penetration and diversify the company’s geographic revenue base over the long run.

PODD currently has a market capitalization of $11.1 billion.

Image Source: Zacks Investment Research

More on the NewsOmnipod 5 is a tubeless AID system designed to simplify diabetes management by automatically adjusting insulin delivery every five minutes based on continuous glucose monitoring (CGM) readings. The waterproof, wearable Pod proactively corrects high glucose levels while helping protect against hypoglycemia, reducing the need for multiple daily insulin injections.

In Spain, the system is approved for individuals aged two years and older with type 1 diabetes and is compatible with Abbott’s FreeStyle Libre 2 Plus and Dexcom’s G7 CGM sensors. According to the company, Spain is home to more than 4.6 million adults living with diabetes, including an estimated 189,000 people and over 18,500 children and adolescents with type 1 diabetes who rely on insulin therapy, underscoring the significant market opportunity for Omnipod 5. Insulet also noted that it is working closely with health authorities, reimbursement agencies and Spain’s autonomous communities to facilitate broader and equitable access to the technology over time.

Alongside Omnipod 5, Insulet introduced Omnipod Discover, its proprietary web-based retrospective data analytics and reporting platform, to the Spanish market. Designed for Omnipod 5 users, caregivers and healthcare professionals, the platform converts diabetes data into clear, actionable insights that can support more personalized treatment decisions and informed therapy discussions. Featuring an intuitive interface and easy-to-understand reports, Omnipod Discover is intended to improve patient engagement while streamlining diabetes management for healthcare providers.

The platform was initially launched in five Middle Eastern countries earlier this year and is set to expand across additional Omnipod 5 markets over the coming year, reflecting Insulet’s broader strategy of complementing its hardware portfolio with digital health capabilities to enhance the overall diabetes care experience.

Favorable Industry Prospect for PODDGoing by the data provided by Grand View Research, the CGM devices market was valued at $15.47 billion in 2026 and is expected to witness a CAGR of 15.1% through 2033.

Factors like the growing cases of diabetes, the increasing adoption of CGM devices, growing clinical needs, technological innovation and shifting care models are boosting the market’s growth. 

A Recent Development by PODDRecently, PODD unveiled positive clinical data for its next-generation Omnipod 6 and investigational fully closed-loop automated insulin delivery systems at the American Diabetes Association's 86th Scientific Sessions. Results from the STRIVE pivotal trial and EVOLUTION 3 feasibility study demonstrated improved glucose control, reduced user effort and enhanced automation, reinforcing the company’s innovation pipeline and long-term leadership in diabetes technology.

PODD’s Zacks Rank & Key PicksCurrently, PODD carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Key Takeaways Insulet is positioned for growth as Omnipod 5 gains users across Type 1 and Type 2 populations. PODD's Omnipod revenues rose 33% in constant currency in Q1 2026, with Omnipod 5 now in 19 countries. Competition, SG&A investments and raw material and shipping costs could pressure PODD's margins. Insulet (PODD - Free Report) is well poised for growth in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery (AID) system for both Type 1 and Type 2 populations. The company is strongly executing against its long-term priorities to drive penetration, deepen competitive advantage, unlock new opportunities and scale profitably. However, macroeconomic pressures and intense competition could pose headwinds for Insulet’s operations.

In the past year, this Zacks Rank #3 (Hold) stock has lost 46.9% compared with the industry’s 27.7% decline. The S&P 500 composite has returned 23.6% in the same time frame.

The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $16.21 billion. The company’s estimated long-term earnings growth rate of 22.2% is well ahead of the industry’s 12.5% growth. PODD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 16.2%.

Let us delve deeper.

Upsides for InsuletOmnipod 5 Gains Market Share: Omnipod 5 remains differentiated as a fully disposable, tubeless AID system that is expanding its installed base across both the U.S. and international markets. In first-quarter 2026, total company revenues grew 30.1% in constant currency, driven by Omnipod revenue growth of 33% in constant currency. 

Management noted that its global customer base grew nearly 25% year over year, driven by higher new customer starts and retention trends consistent with the prior year. In the United States, growth included greater seasonality tied to deductible resets, but new customer starts improved through the quarter and into early second quarter. Internationally, growth continues to be supported by new customer starts and the conversion from Omnipod DASH to Omnipod 5, with Omnipod 5 now available in 19 countries. 

Progress With Strategic Actions: Insulet is focused on driving growth in the global automated insulin-delivery market by expanding sensor connectivity and enhancing the Omnipod 5 experience. In the first quarter of 2026, the company completed a limited U.S. launch of Omnipod 5 integrated with Abbott Laboratories’ FreeStyle Libre 3 Plus and plans a broader rollout of the Libre 3 Plus integration and its latest algorithm update in the coming weeks.

Image Source: Zacks Investment Research

The company also enrolled the first participant in the EVOLVE pivotal study, which is intended to support a 510(k) filing in 2027. Supporting these initiatives, management raised its 2026 outlook, forecasting total company revenue growth of 21-23% and Omnipod revenue growth of 22-24%, while maintaining expectations for adjusted EPS growth of more than 25% for the year.

What Ails Insulet?Tough Competitive Pressure: Insulet competes against large, established diabetes device companies and newer entrants offering pumps, smart pens, and other insulin delivery approaches. As AID adoption expands globally, management expects competition to increase, which can raise commercial spending requirements and heighten payer negotiations. 

In the first quarter of 2026, SG&A expense increased 21.7% year over year as Insulet invested in sales force expansion, demand generation and customer experience programs. Over time, competitive intensity can reduce revenue growth durability or limit the pace of operating margin expansion, which is mentioned in 2026 guidance.

Economic Uncertainty and Supply Exposure: Insulet operates in a global healthcare supply chain that remains exposed to geopolitical and macro uncertainty. Management cited incremental raw material and shipping costs tied to the ongoing conflict in the Middle East as an offset to its 2026 margin outlook. These factors may lengthen sales cycles, increase cost variability and reduce visibility into achieving the company’s 2026 operating-margin expansion target.

PODD Stock Estimate TrendThe Zacks Consensus Estimate for Insulet’s 2026 earnings per share has remained unchanged at $6.46 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $3.31 billion, implying a 22.2% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.